Fractyl Health, Inc. (NASDAQ: GUTS) is among the 11 Best New Penny Stocks to Buy Right Now, with Canaccord Genuity reiterating a “Buy” rating and $12 price target on July 18. The decision followed the company sharing new data from its Phase 3 trial of Revita.

Canaccord Genuity held discussions with physicians from large academic hospitals in the US regarding Fractyl Health’s ongoing Phase 3 trial for Revita. While opinions on the Revita procedure varied, all physicians agreed that controlled data is necessary for a full clinical assessment.

Canaccord Genuity anticipates Revita to achieve 1% peak penetration in the weight maintenance population with a 60% probability of success, projecting peak sales of $400 million in 2031. Fractyl Health focuses on metabolic therapeutics targeting the root causes of obesity and type 2 diabetes.

While acknowledging GUTS’s investment potential, Canaccord Genuity believes certain AI stocks offer greater upside with lower downside risk. For those seeking an undervalued AI stock benefiting from Trump-era tariffs and the onshoring trend, consider their free report on the best short-term AI stock.

Read more at Yahoo Finance: Canaccord Genuity Reiterates Buy Rating on Fractyl Health (GUTS)